Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

RFID meeting

This article was originally published in The Tan Sheet

Executive Summary

A public workshop Feb. 8-9 will allow FDA's Counterfeit Drug Task Force to collect stakeholder input on identifying "incentives for widespread adoption of radio frequency identification (RFID), as well as obstacles," according to a Federal Register announcement Jan. 11. Specifically, the agency seeks input on how to address the likelihood that widespread RFID technology will not be in operation by the current deadline for implementation under the Prescription Drug Marketing Act's pedigree requirements. Comments will "guide the agency's decision whether to continue the delayed effective date, let the regulatory provisions go into effect, or take other steps," the announcement states. In 2004, FDA cited implementation of electronic track and trace capability by 2007 as a priority. However, "it appears that the goals described previously may not be met," FDA states...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099012

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel